Seeking Alpha

Medivation (MDV) and Astellas (ALPMF.PK) enroll the first patient in a Phase II trial for...

Medivation (MDV) and Astellas (ALPMF.PK) enroll the first patient in a Phase II trial for enzalutamide, a treatment for triple-negative breast cancer, for which "there are no approved targeted therapies." The trial will recruit approximately 80 patients, who will take enzalutamide orally once a day. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)